Clomacran
Appearance
Clinical data | |
---|---|
Trade names | Devryl, Olaxin,[1] Develar[2][3] |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H21ClN2 |
Molar mass | 300.83 g·mol−1 |
3D model (JSmol) | |
Density | 1.120 g/cm3 [1] |
| |
|
Clomacran is an antipsychotic drug of the acridines class, developed in the 1970s[2] by the pharmaceutical company Smith, Kline & French under the brand names Devryl and Olaxin.[1]
It was withdrawn from the market in the UK, due to liver toxicity, in 1982.[5][6][7]
References
- ^ a b c "Clomacran | 5310-55-4". ChemicalBook. Retrieved 2023-08-25.
- ^ a b Elks, J.; Ganellin, C. R., eds. (1990). Dictionary of Drugs. Boston, MA: Springer US. p. 297. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2087-7.
- ^ "Substâncias e remédios sob controle" [Substances and drugs under control] (PDF). Jornal do Brasil (in Brazilian Portuguese). 1986-11-05. p. 14. Archived (PDF) from the original on 2023-08-08. Retrieved 2023-08-08.
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-03.
- ^ a b Dixit, Nandan; Patel, Chirag; Bhavsar, Mansi; Patel, Saumya; Rawal, Rakesh; Solanki, Hitesh (2022-05-02). "Quantitative Structure-activity Relationship (QSAR) study of Liver Toxic Drugs". International Association of Biologicals and Computational Digest: 63–71. doi:10.56588/iabcd.v1i1.17. eISSN 2583-3995.
- ^ "Clomacran". PubChem. Retrieved 2023-08-25.
- ^ Andrews, Elizabeth B.; Moore, Nicholas, eds. (2014). Mann's Pharmacovigilance (1 ed.). Wiley. doi:10.1002/9781118820186. ISBN 978-0-470-67104-7.